REPLIGEN CORP Payments to Acquire Businesses, Gross
REPLIGEN CORP (RGEN) reported Payments to Acquire Businesses, Gross of $182.15 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesGross · last filed 2020-02-26
- REPLIGEN CORP payments to acquire businesses, gross for the quarter ending 2019-12-31 was $0.00.
- REPLIGEN CORP payments to acquire businesses, gross for the quarter ending 2019-09-30 was -$22.00K.
- REPLIGEN CORP payments to acquire businesses, gross for the quarter ending 2014-12-31 was $0.00.
- REPLIGEN CORP payments to acquire businesses, gross for the quarter ending 2014-09-30 was $63.00.
- REPLIGEN CORP payments to acquire businesses, gross for fiscal 2019 was $182.15M.
- REPLIGEN CORP payments to acquire businesses, gross for fiscal 2017 was $112.80M, a 152.82% increase from fiscal 2016.
- REPLIGEN CORP payments to acquire businesses, gross for fiscal 2016 was $44.61M.
- REPLIGEN CORP payments to acquire businesses, gross for fiscal 2014 was $21.24M.
| Period end | Payments to Acquire Businesses, Gross | Payments to Acquire Businesses, Gross as first filed | Payments to Acquire Businesses, Gross 3 month | Payments to Acquire Businesses, Gross 6 month | Payments to Acquire Businesses, Gross 9 month | Payments to Acquire Businesses, Gross 9 month as first filed | Payments to Acquire Businesses, Gross 12 month | Payments to Acquire Businesses, Gross 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$22.00K derived: sum of 2 quarters · filed 2020-02-26 | $182.15M 10-K · filed 2020-02-26 | |||||
| 2019-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $182.15M 10-Q · filed 2019-10-31 | ||||||
| 2019-06-30 | $182.18M 10-Q · filed 2019-08-01 | |||||||
| 2017-12-31 | $112.80M 10-K · filed 2020-02-26 | |||||||
| 2016-12-31 | $44.61M 10-K · filed 2019-03-01 | |||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $63.00 derived: sum of 2 quarters · filed 2017-02-23 | $21.24M 10-K · filed 2017-02-23 | $21.24M 10-K · filed 2015-03-17 | ||||
| 2014-09-30 | $63.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $21.24M 10-Q · filed 2015-11-05 | $21.24M 10-Q · filed 2014-11-07 | |||||
| 2014-06-30 | $21.24M 10-Q · filed 2015-08-06 | |||||||
| 2014-06-02 | $21.17M 10-K · filed 2016-02-25 | $21.17M 10-K · filed 2015-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |